Nuevos anticoagulantes orales: actualización

por Berkovits,Alejandro, Mezzano,Diego
Publicado 2017

Evaluación de la anticoagulación con rivaroxaban, en pacientes con fibrilación auricular no valvular de reciente diagnóstico

por Neira,Víctor, Corbalán,Ramón, Pereira,Jaime, Panes,Olga, Garayar,Bernardita, Aizman,Andrés, Llevaneras,Silvana, Villarroel,Luis
Publicado 2016

Rivaroxaban para el tratamiento de la trombocitopenia inducida por heparina. Caso clínico

por Rivera O.,Gustavo, Corsi S.,Oscar, Pavlovic J.,Andrés, Aizman S.,Andrés, Varas A.,Pablo
Publicado 2017

Nuevos anticoagulantes orales en la prevención del ataque cerebrovascular

por Soto V,Álvaro, Cárcamo P,Daniel A
Publicado 2012

Rivaroxaban triggered multifocal intratumoral hemorrhage of the cabozantinib-treated diffuse brain metastases: A case report and review of literature

por Chen Luyue, Chen E, Huang Yanlin, Tian Xinhua
Publicado 2021

Anti-Xa Inhibitor-Induced Hemorrhagic Pruritic Rash: A Case Report on Possible Cross-Reactivity Between Apixaban and Rivaroxaban

por Anis TR, Jandreau W
Publicado 2021

Rivaroxaban‐calibrated chromogenic anti‐Xa assay in cirrhosis: Use to rule out disseminated intravascular coagulation

por Fabienne Lucas, Michael S. Stecker, Olga Pozdnyakova, Jean M. Connors, Elisabeth M. Battinelli
Publicado 2021

Benefit–Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER

por Gary E. Raskob, Alex C. Spyropoulos, Theodore E. Spiro, Wentao Lu, Zhong Yuan, Bennett Levitan, Eunyoung Suh, Elliot S. Barnathan
Publicado 2021

Conservative management of massive rivaroxaban overdose: A case report and literature review

por Alireza Ghodsi, Leila Etemad, Bita Dadpour, Babak Mostafazadeh, Mohammad Moshiri
Publicado 2021

Characteristics and Outcomes of Patients With Deep Vein Thrombosis Diagnosed in Emergency Department of Clinical Hospital Dubrava During 2019

por Ivan Radilj, Vlatko Grabovac, Zdravko Mitrović
Publicado 2021

Does Warfarin or Rivaroxaban at Low Anticoagulation Intensity Provide a Survival Benefit to Asian Patients With Atrial Fibrillation?

por Dong Lin, Dong Lin, Yequn Chen, Yequn Chen, Yequn Chen, Jian Yong, Shiwan Wu, Yan Zhou, Weiping Li, Weiping Li, Xuerui Tan, Xuerui Tan, Xuerui Tan, Ruisheng Liu
Publicado 2021

Thromboprophylaxis for Children Post‐Fontan Procedure: Insights From the UNIVERSE Study

por Brian W. McCrindle, Alan D. Michelson, Andrew H. Van Bergen, Estela Suzana Horowitz, Juan Pablo Sandoval, Henri Justino, Kevin C. Harris, John L. Jefferies, Liza Miriam Pina, Colleen Peluso, Kimberly Nessel, Wentao Lu, Jennifer S. Li
Publicado 2021

Design and Baseline Data for a Prospective Observational Study of Rivaroxaban in Patients with Venous Thromboembolism in Japan (XASSENT)

por Ikuo Fukuda, Atsushi Hirayama, Kazuo Kawasugi, Takao Kobayashi, Hideaki Maeda, Mashio Nakamura, Norifumi Nakanishi, Norikazu Yamada, Tsubasa Tajima, Sanghun Iwashiro, Yutaka Okayama, Toshiyuki Sunaya, Kazufumi Hirano, Takanori Hayasaki
Publicado 2021

Evaluation of the Determination of Dabigatran, Rivaroxaban, and Apixaban in Lupus Anticoagulant-Positive Patients

por Jana Úlehlová, Barbora Piskláková, Eliška Ivanovová, Jana Procházková, Pavla Bradáčová, Aleš Kvasnička, David Friedecký, Luděk Slavík
Publicado 2021

Direct oral anticoagulants; a review for the non-specialist

por Thilina Gunawardena
Publicado 2021

Stroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulants

por Turagam MK, Velagapudi P, Flaker GC
Publicado 2015

Rivaroxaban in acute venous thromboembolism: UK prescribing experience

por Victoria Speed, Jignesh P. Patel, Derek Cooper, Stephen Miller, Lara N. Roberts, Raj K. Patel, Roopen Arya
Publicado 2021

Comparison of the Endoscopic Picture in Case of Complications of the upper Gastrointestinal Tract Caused by the Use of Antithrombotic Agents and Non-Steroidal Anti-Inflammatory Dru...

por E. V. Moroz, A. Y. Karateev, E. V. Kryukov, A. A. Sokolov, E. N. Artemkin
Publicado 2019

The Effect of Rivaroxaban on CYP4F2 and Transcription Factors’ Activity in HUVECs

por Ieva Ciapiene, Vacis Tatarunas, Agne Giedraitiene, Vaidotas Zvikas, Valdas Jakstas, Audrone Veikutiene, Ugne Meskauskaite, Ugne Venckyte, Audrius Pukalskas, Vaiva Lesauskaite
Publicado 2021